KKL 顾客使用本产品发表的 0 篇科研文献

Anti-Mouse PD-1 Antibody (29F.1A12) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse PD-1. Anti-Mouse PD-1 Antibody (29F.1A12) blocks the binding of PD-1 to its two ligands, PD-L1 and PD-L2. Anti-Mouse PD-1 Antibody (29F.1A12) can be used for the researches of cancer and immunology, such as CT26 tumor and pancreatic cancer.

PD-1

When Anti-Mouse PD-1 Antibody (29F.1A12) (10 μg/mL, 7 days) is used in combination with anti-CTLA-4, it can increase the production of IFN - γ cytokines and Ki-67 expression in CD8+CTLA-4+PD-1+tumor infiltrating lymphocytes from CT26 tumors.

The combination of Anti-Mouse PD-1 Antibody (29F.1A12) (200 μg, intraperitoneal injection, administered on days 10, 13, and 16) and anti-CTLA-4 can induce tumor regression in CT26/ID8-VEGF tumor cells.
Anti-Muse PD-1 Antibody (29F.1A12) (100 μg, intraperitoneal injection, administered on days 1, 3, and 5 after BRAF inhibitor administration) can be used in combination with BRAF inhibitors to delay tumor growth and improve survival rates in small BP tumors.
Anti Mouse PD-1 Antibody (29F. 1A12) (200 μg, intraperitoneal injection, administered on the 4th, 7th and 10th days), in combination with the PRIP1 inhibitor, can protect pancreatic cancer from primary pancreatic cancer and liver metastasis.

 

150 kDa

Shipping with dry ice.

Store at -80°C for 2 years. Aliquots should be stored at the same temperature after first use to avoid multiple freeze-thaws

Programmed cell death protein 1 (CD279/PD-1) is a ~31 kDa protein. Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self. Delivers inhibitory signals upon binding to ligands, such as CD274/PDCD1L1 and CD273/PDCD1LG2. Following T-cell receptor (TCR) engagement, PDCD1 associates with TCR-CD3 in the immunological synapse and directly inhibits T-cell activation. Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival. CD279 is the therapeutic target of pembrolizumab (Keytruda) and nivolumab (Opdivo).

Mouse

Rat

Rat IgG2a kappa

Q02242

in vivo blocking of PD-1/PD-L signaling; in vitro PD-1 neutralization; Immunohistochemistry (froze)， FCM, IF, IHC, Neutralization, WB

Liquid

0.01M PBS pH 7.4

18566 [NCBI]

>95% as determined by SDS-PAGE

<1 EU/mg

The product can be reconstituted/diluted with sterile PBS or saline.

Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279

29F.1A12

Monoclonal

Rat IgG2a kappa, Isotype Control